Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp owering of low-density lipoprotein-cholesterol (LDL-C) with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) has been shown to reduce cardiovascular mortality and morbidity. 1-4 Many multicenter trials found that statin therapy produced plaque regression and stabilization as seen on intravascular ultrasound (IVUS). 5-8
Stabilization and Regression of Coronary Plaque
loss of yellow color occurred prior to volumetric plaque regression on atorvastatin therapy. The different time courses of these changes suggested that the improvement in plaque characteristics occurred early, whereas atheroma volume reduction occurred over a prolonged period of time.
The aim of the present study was therefore to investigate the effects of fixed dose (2 mg) pitavastatin on the stabilization and regression of yellow plaque on coronary angioscopy and IVUS (TOGETHAR) during a period of 52 weeks.
Methods

Study Design and Patient Population
The study was designed as a prospective open-label trial to assess the effects of 52 weeks of treatment with pitavastatin on angioscopy and IVUS of quantitative or qualitative changes in atherosclerosis at yellow plaques.
Patients with suspected or known coronary artery disease (CAD) complicated by hypercholesterolemia, with a fasting LDL-C level ≥120 mg/dl within 4 weeks of study initiation were initially screened. After angioscopy, patients having yellow plaque, color intensity higher than grade 2 were enrolled.
Exclusion criteria were administration of pitavastatin before enrollment, intolerance or contraindication to statin, acute myocardial infarction, homozygous familial hypercholesterolemia undergoing apheresis, presence of malignancies or mental disorder within 5 years prior to enrollment, progressive hepatic disorder, treatment with dialysis, serum creatinine ≥2 mg/dl or creatine kinase ≥500 IU/L, and uncontrolled diabetes with hemoglobin A1c ≥8.0%.
All eligible patients received a daily dose of oral pitavastatin 2 mg/day for 52 weeks. Coronary angiography was performed at week 0 (baseline) and at week 52.
The study protocol was approved by the Institutional Review Boards of Osaka Police Hospital. All patients provided written informed consent before participation.
Angioscopy
Immediately after coronary angiography, baseline angioscopy images were obtained with a Fiber Imaging System FT-201 (FiberTech Co Ltd, Tokyo, Japan) and the Console (Intertec Medicals Co Ltd, Osaka, Japan), using a previously described technique. 9-20 From these images, lesions located in major coronary arteries were selected for the main angioscopy examination. Lesions close to culprit plaques treated by percutaneous coronary intervention, that is, those within 5 mm, were excluded. Percent stenosis was not used for selection of the lesion for angioscopy because plaque color is not necessarily related to it. Images were recorded on a digital videotape and yellow plaque graded using a 5-point scale: 0, not yellow at all; 1, pale yellow; 2, yellow; 3, deep yellow; 4, bright yellow. 13 Already ruptured plaque was excluded. One maximum yellow grade per patient at baseline was determined. Vulnerable plaque was defined as ≥grade 2.
The positions of the plaques were identified on fluoroscopy by determining the location of the fiberscope tip and making a plaque map. The angioscopically most progressed plaque of each patient was identified. At week 52 the position of the maximum yellow grade at baseline was observed on angioscopy, in reference to the positions of side branches used as landmarks at baseline. For determining the color grade, all angioscopy images were reviewed by 2 independent investigators who were unaware of the patients' data and the time of image acquisition. The discordant plaques were intensively reevaluated by the reviewers, but if there was still discordance between them after the second evaluation, they further evaluated the images individually until they reached consensus. During this process, the images were completely blinded to the investigators in terms of patient identity and time of acquisition.
IVUS Image Acquisition
IVUS measurements were performed with a 2.6-F 40-MHz Atlantis Pro IVUS catheter and Clear View Imaging System (Boston Scientific Corporation, Natick, MA, USA). The IVUS probe was advanced to a side branch located distal to the target lesion and images were obtained during automatic pullback at a rate of 0.5 mm/s and recorded on s-VHS videotape.
Based on the plaque map in which yellow plaque was located on angioscopy, IVUS volumetry of the target lesions were conducted using at least 10-mm segment (IVUS analysis segment) at lesion sites as the unit of analysis at week 0 and week 52. At baseline examination the IVUS analysis segment was determined to include the plaque with the maximum yellow intensity, based on the plaque map and the position of a side branch. At the examinations performed at week 52, the IVUS analysis segment was set using a side branch as a landmark to ensure that the same position was imaged on IVUS. The boundary of the lumen and external elastic membrane was traced semi-automatically on digitized cross-sections of the IVUS analysis segment every 0.1 mm using a 3-D analysis system (echoPlaque2, INDEC Systems, CA, USA). Percent atheroma volume (PAV) was calculated as described in previous reports. 3, 11 IVUS volumetry was performed at a core laboratory in the Nihon University School of Medicine by an operator who was not involved in the medical care of the patients. Two investigators independent of the core laboratory and blinded to the patients' identity and time of image acquisition individually evaluated the images, including the accuracy of target lesion analysis at baseline and at week 52.
Data Matching in the Primary Analysis
The coronary segments ≥10 mm that included the angioscopically most progressed plaque of each patient were analyzed on IVUS. Data for a plaque that had undergone angioscopic colorimetry and IVUS volumetry at baseline and at week 52 were treated as "matched data". Maximum yellow grade per KODAMA K et al. KODAMA K et al.
patient at week 52 was compared with baseline. When multiple yellow plaques were included in a single 20-mm IVUS analysis segment, the maximum value of the color grades was used. For this reason, if any yellow plaques observed at baseline in an IVUS analysis segment were unable to be reevaluated angioscopically at week 52 because of procedural difficulties, the set of plaques and the IVUS analysis segment in question were excluded from the analysis.
Statistical Analysis
Because this study was designed as preliminary exploratory research to investigate the relationship between quantitative and qualitative changes of coronary atherosclerotic plaques, the number of patients to be screened was planned as 100. The Wilcoxon signed-rank test was used for comparison of plaque color grade between the data before and after treatment. With respect to the IVUS variables, the paired t-test was used to compare the data. The t-test was performed to compare LDL-C and high-density lipoprotein-cholesterol (HDL-C) levels before and after treatment. In all tests, P<0.05 was considered statistically significant.
Results
Patient Population
Between November 2004 and June 2006, 100 patients who gave informed consent to participate in the study and were satisfied with the entry criteria were screened. A total of 90 patients were followed for 52 weeks and, of these 90 patients, 78 patients had yellow plaque ≥grade 2, suggesting vulnerable plaque. Among them, 46 patients had matched angioscopy and IVUS data. Therefore, 46 segments that included plaques of maximum yellow grade on angioscopy were used in the present study. The baseline patient characteristics are shown in Table 1 . (Table 2) LDL-C was reduced 34.5% (145.0±24.0 mg/dl to 93.6± 22.6 mg/dl, P<0.001), and HDL-C increased 17.8% (44.9± 11.1 mg/dl to 51.9±11.7 mg/dl, P<0.001). The mean LDL-C/ HDL-C ratio was reduced from 3.4 at baseline to 1.9 at week 52. High sensitive C-reactive protein was reduced from 2.2± 4.6 mg/L at baseline to 0.9±1.2 mg/L at week 52 (P<0.011).
Change in Laboratory Data
Changes in Angioscopy Findings
The yellow grade was significantly reduced from 2.9±0.8 (95% confidence interval (CI) =2.7-3.1) at baseline to 2.6± 0.7 (95%CI =2.4-2.8, P<0.04) at week 52 (Figure 1) . The change of yellow grade was inversely correlated with maximum yellow grade at baseline (Spearman's rank correlation coefficient -0.654, P<0.001; Figure 2 ). There was no correlation between serum LDL-C level at week 52 and changes of yellow grade during 52 weeks ( Figure 3A) . There was also no correlation between changes of serum LDL-C level after 52 weeks and changes of yellow grade after 52 weeks ( Figure 3B ).
Changes in IVUS Findings
The length of the measured segment was 17.55±8.60 mm, ranging from 10.00 mm to 52.83 mm. PAV at baseline (47.2± 8.6%) did not decrease significantly (-0.1±3.8%; 95%CI = -1.2 to 1.0) by week 52 (47.1±8.9%, P=0.859; Table 3 ). The change of PAV was correlated with LDL-C at week 52 (Spearman's rank correlation coefficient 0.312, P=0.035; Figure 3C ).
Adverse Events
Major adverse clinical events consisted of 1 occurrence of unstable angina and 1 occurrence of acute heart failure. Other adverse drug effects were 2 occurrences of hypertension, 2 of gamma-glutamyltransferase increase, 1 of eczema, 1 of blood creatine phosphokinase increase, 1 occurrence of myoglobin blood increase, 1 of glucose urine, 1 of arthralgia, 1 of diabetes mellitus, 1 occurrence of alanine aminotransferase increase, and 1 occurrence of aspartate aminotransferase increase.
Discussion
Pathologically, plaque rupture and acute thrombotic occlusion occur at the site of vulnerable plaques, which contain lipid-rich plaque covered by a thin fibrous cap. 21,22 A previous study comparing angioscopy and optical coherence tomography in vivo demonstrated that more intensely yellow plaque has a thinner fibrous cap. 23 This close relation between yellow color intensity and the thickness of the fibrous cap has also been reported in an ex vivo study, using integrated backscatter IVUS and angioscopy on tissue isolated autopsied specimen. 24 Pan-coronary screening using angioscopy showed that coronary arteries have multiple yellow plaques in patients with acute coronary syndrome, 19 and the number of yellow plaques correlated with the risk of acute coronary syndrome. 20 The current prospective trial using angioscopy for coronary vulnerable plaques during 52 weeks of pitavastatin therapy showed reduction of plaque yellow grade. The mean change in angioscopic yellow grade was not large, a 0.3-point decrease after 52 weeks; but plaques of higher yellow grade at baseline tend to be stabilized more. This implies that highly vulnerable plaques were stabilized effectively by pitavastatin and may result in the prevention of cardiac event and improvement of prognosis in patients with coronary heart disease. Plaque regression is thought to involve a different mechanism from the reduction of cardiovascular events by treatment with statins. Based on the previous reports, plaque regression may be dependent on both the type of coronary artery disease and the decrease in LDL-C. Plaque regression occurred more commonly in patients with acute coronary syndrome 25, 26 rather than in patients with stable angina. 5 None of the present study patients had acute coronary syndrome, and the present results on IVUS did not show evidence of plaque reduction. Because a fixed dose of pitavastatin was used according to the present study protocol, the decrease in LDL-C level was small. The achieved LDL-C level after treatment in the Stabilization and Regression of Coronary Plaque present study was 90 mg/dl, which was higher than that in the TWINS study. This might explain the insignificant plaque reduction. In the previous TWINS study, no patient was treated with statin prior to initiation of atorvastatin administration, but 8.7% of patients were already treated with another statin other than pitavastatin before enrollment in that study. Previous statin treatment might have made plaques resistant to regression by statin treatment in that study. In the COSMOS study, plaque regression was minimal in the previous statin treatment group compared to the de novo statin treatment group. 27 Significant plaque progression was not observed in the present study and the result was comparable to the previous large-scale trial and compatible with the curve shown in Figure 4 . Some previous reports described that plaque stabilization and regression did not occur simultaneously. 24, 28 Hirayama et al reported that plaque stabilization occurred prior to plaque regression in the TWINS study. 13 These results suggested that plaque stabilization and plaque regression reflect independent processes mediated by different mechanisms. In the present study the reduction of PAV determined on IVUS had a significant correlation with the reduction of LDL-C level. This correlation was also reported in the previous large-scale trials, suggesting that the reduction of LDL-C change might alter lipid transport from plaque to blood. In contrast, the reduction of plaque color intensity following treatment was not correlated with the LDL-C level at week 52 or change of LDL-C level. The change of plaque color might be an independent mechanism from the reduction of LDL-C. The early change of plaque color might explain the early benefit as shown in MIRACL 2 or PROVE-IT. 29 In PROVE-IT, the early benefit of atorvastatin compared to pravastatin was explained by the difference of anti-inflammatory effects between 2 statins. Using an animal model, Yokoyama et al demonstrated the anti-inflammatory effect of pitavastatin, inhibiting neointimal hyperplasia after stenting by a reduction of inflammatory reactions. 30 Recently, Takarada et al reported that lipid-lowering therapy with statin for 9 months after the onset of acute myocardial infarction significantly increased the fibrous cap thickness in patients with hyperlipidemia. 31 Taking these results into consideration, the change of plaque color might be due to anti-inflammatory effects of pitavastatin. There was no evidence for this in the present study, and further studies are needed to clarify the mechanism contributing to the plaque stabilization shown by the color changes.
A higher dose of pitavastatin with greater reduction of LDL-C level might be required for significant plaque regression as shown in the JAPAN-ACS study, 26 but some reports implied that early coronary events decreased without plaque regression by statin. 2, 29 Coronary angioscopy may play a role in this explanation. Plaque stabilization on angioscopy and subsequent plaque regression on IVUS occurred after atorvastatin therapy in the TWINS study. 13 The present results demonstrated that plaque stabilization on angioscopy occurred without plaque regression following treatment with 2 mg pitavastatin. Moreover, stabilization was independent from the LDL-C level at week 52 and the change of LDL-C level after 52 weeks. These results including those from previous studies suggest that pitavastatin may contribute to prevent cardiovascular events by multiple mechanisms leading to plaque regression dose dependently, and also to early yellow grade reduction dose independently.
Conclusions
Despite the higher age of the present patients, pitavastatin therapy stabilized coronary vulnerable plaque by diminishing yellow color intensity observed on angioscopy. Stabilization was independent of the LDL-C level at week 52 and the difference of PAV that might be related to the change of LDL-C level. These results suggest that concomitant monitoring on angioscopy and IVUS for plaque stabilization and regression is important and that the mechanisms underlying the stabilization and regression of atherosclerotic plaques by statins may differ but contribute to the reduction of cardiovascular events.
